Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma

Exclusion Criteria

• •Known central nervous system (CNS) involvement by lymphoma
• •Known hepatitis infection
• •Known HIV positivity
• •Known history of renal disease with proteinuria; urine protein:creatinine ratio ³1.0 at screening
• •Uncontrolled hypertension: blood pressure of \>150/100 mmHg at screening
• •Unstable angina
• •History of myocardial infarction within 6 months
• •History of stroke within 6 months
• •Clinically significant peripheral vascular disease
• •New York Heart Association (NYHA) Grade II or greater congestive heart failure
• •Patient has ejection fraction \< 50%
• •Patient is taking coumadin, or has known history of thrombosis within last 6 months
• •Evidence of bleeding diathesis or coagulopathy
• •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study
• •Minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 1
• •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
• •Serious, non-healing wound, ulcer, or bone fracture
• •Concomitant malignancies or previous malignancies within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• •Patient is pregnant or nursing
• •Patient is receiving other investigational drugs